Bulletin from the Extraordinary General Meeting August 31, 2026 in Boule Diagnostics

31 Aug, 2026

Corporate Information English General meeting IR Listing Regulation News Regulatory Report of the AGM

The Extraordinary General Meeting (the “EGM”) resolved to approve a loan from one of the company’s major shareholders, AB Grenspecialisten, in accordance with the Board of Directors’ proposal.

Complete proposals regarding the resolution of the EGM as set out above are available on Boule’s website, www.boule.com.

About Us
Boule Diagnostics AB (publ) is a global company consisting of two business segments, Diagnostics and OEM CDS. Diagnostics is specialized in near-patient, decentralized diagnostic solutions for human and veterinary applications, serving hospitals, clinics, laboratories. OEM CDS develops and delivers reliable reagent, blood controls and calibrators tailored for diagnostic companies worldwide.
With operations in Sweden, the United States, Mexico, and Russia, and a global distribution network spanning more than 100 countries, Boule combines a resilient business model with strong positions in key growth markets. In 2025, Boule reported net sales of SEK 490 million and has about 200 employees worldwide. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com

Bulletin from the Extraordinary General Meeting August 31, 2026 in Boule Diagnostics

Bulletin from the Extraordinary General Meeting August 31, 2026 in Boule Diagnostics

Latest news

Related news in Corporate Information

Boule Diagnostics AB: Boule Diagnostics – Inbjudan till presentation av delårsrapport Q1 2024

KALLELSE TILL ÅRSSTÄMMA I BOULE DIAGNOSTICS AB

Boule Diagnostics – Inbjudan till presentation av Q1 2025

Boule Diagnostics – Invitation to presentation of the interim report Q1 2025